Home Gilead Announces Phase 2 Results for Two Investigational All-Oral Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C
 

Keywords :   


Gilead Announces Phase 2 Results for Two Investigational All-Oral Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C

2014-04-10 13:18:10| Biotech - Topix.net

Gilead Sciences, Inc. today announced data from two Phase 2 studies evaluating investigational all-oral regimens containing the nucleotide analog polymerase inhibitor sofosbuvir for the treatment of chronic hepatitis C virus infection.

Tags: c results treatment phase

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
15.11 PORTABLE
15.11HG 5R
15.11 ST MAX 5W FLEX S
15.11
15.1189 560 STH
15.11 adidas F50 27.5
15.11 SAMANTHA VEGA
15.1150
More »